

Global Point Prevalence Survey of Antimicrobial Consumption and Resistance

Outpatient Module




**EXAMPLE REPORT
WITH FICTIONAL DATA**

Institution ID: 0000
Your Facility Name
Your facility type
Survey: 2023–P1

Participation to outpatient Global-PPS by UN macro-geographical regions, years 2023 – 2024

	Number of countries	Number of facilities
North America	1	3
South America	1	1
Africa	8	84
Europe	4	24
West & Central Asia	1	4
East & South Asia	1	2
Australia & New Zealand	0	0



North America
Latin America
Africa

West & Central Asia
East & South Asia

Europe
Australia & New Zealand

Explanatory notes for this Global–PPS outpatient feedback report

Below each slide extra information is provided to help you to correctly interpret the results.

The slides present the results for your facility, your country, your region according to the UN classification, merged results on the facility type for your region and Europe.

Below each slide you find the designation of your own country, your region and facility type displayed.

Reference data include validated data from the current or most recent year with a minimum number of 4 institutions for the country and facility type at country level. Some facility types are merged for the reference data: Primary/Secun. hosp includes primary and secondary care hospitals; Tertiary/Spec/Inf.dis. hosp includes tertiary care hospitals, specialized and infectious disease hospitals; Outpatient services include outpatient clinics and primary healthcare facilities. Reference data for the continent and Europe include at least 6 institutions belonging to any facility type.

Reference data: country – 2024 (N = 17), continent – 2024 (N = 19), facility type – 2023 (N = 6), EU – 2024 (N = 23).

Results at country level are not displayed if there are less than 4 facilities participating during the current or any of the previous years.

Table of contents

Title	Slide	Title	Slide
Participation to outpatient G-PPS	2	Proportional antibiotic use ATC4 level – neonate	24
Explanatory notes for this report	3	Ten most common diagnoses for antimicrobial prescribing	25
Table of contents	4	Ten most common diagnoses for antimicrobial prescribing – adult	26
Antimicrobial prevalence by age	5	Ten most common diagnoses for antimicrobial prescribing – child	27
Antimicrobial prevalence by unit	6, 7	Ten most common diagnoses for antimicrobial prescribing – neonate	28
Antimicrobial prevalence by unit – adult	8, 9	Top 5 antimicrobials for top 5 diagnoses	29 – 33
Antimicrobial prevalence by unit – child	10, 11	Top 5 antimicrobials for top 5 diagnoses – adult	34 – 38
Antimicrobial prevalence by unit – neonate	12	Top 5 antimicrobials for top 5 diagnoses – child	39, 40
Prevalence antimicrobial types	13	Explanatory notes AWaRe slides	41
Prevalence antimicrobial types – adult	14	Proportion AWaRe classification among antibiotics	42
Prevalence antimicrobial types – child	15	Proportion AWaRe classification among antibiotics – adult	43
Prevalence antimicrobial types – neonate	16	Proportion AWaRe classification among antibiotics – child	44
Proportional antibiotic use ATC3 level	17	Proportion AWaRe classification among antibiotics – neonate	45
Proportional antibiotic use ATC3 level – adult	18	Explanatory notes Guideline Compliance slides	46
Proportional antibiotic use ATC3 level – child	19	Guideline compliance	47
Proportional antibiotic use ATC3 level – neonate	20	Guideline compliance – adult	48
Proportional antibiotic use ATC4 level	21	Guideline compliance – child	49
Proportional antibiotic use ATC4 level – adult	22	Guideline compliance – neonate	50
Proportional antibiotic use ATC4 level – child	23		

Antimicrobial prevalence per age group (adult, child, neonate)

	Total	Adult	Child	Neonate
Our facility 2023–P1				
patients (N)	207	150	51	6
treated patients (%)	34.3	32.7	41.2	16.7
Country				
patients (N)	467	268	198	1
treated patients (%)	63.4	54.9	74.7	100.0
Continent				
patients (N)	1807	1313	484	10
treated patients (%)	37.1	31.9	51.9	10.0
Facility type				
patients (N)	204	136	67	1
treated patients (%)	97.1	97.1	97.0	100.0
Europe				
patients (N)	5510	4192	1314	4
treated patients (%)	11.5	12.1	9.7	25.0

Patients (N) = number of patients seen in the outpatient unit(s).

Treated patients (%) = $100 \times (\text{number of patients treated with at least 1 antimicrobial} / \text{number of all patients})$.

Country: Your country ; Continent: Your continent ; Facility type: Your facility type

Adults are over 18 years old. Children are 1 month – 17 years old. Neonates are up to 1 month old.

Antimicrobial prevalence by type of units (1)

	Total	ANC	DEN	EM	ENDO	ENT	EYE	GAS	GM	GP
Our facility 2023–P1										
patients (N)	207		12	41					79	33
treated patients (%)	34.3		16.7	24.4					57.0	15.2
Country										
patients (N)	467		1	44					308	92
treated patients (%)	63.4		100.0	20.5					60.7	85.9
Continent										
patients (N)	1807	143	37	43		112	76	7	947	124
treated patients (%)	37.1	25.2	43.2	25.6		20.5	2.6	0.0	42.2	66.9
Facility type										
patients (N)	204								204	
treated patients (%)	97.1								97.1	
Europe										
patients (N)	5510		1	462	3	257	111	106	3676	1
treated patients (%)	11.5		100.0	12.8	0.0	16.7	1.8	22.6	9.9	100.0

Patients (N) = number of patients seen in the outpatient unit(s).

Treated patients (%) = 100*(number of patients treated with at least 1 antimicrobial/number of all patients).

Country: Your country; Continent: Your continent; Facility type: Your facility type

Total=overall prevalence for all units combined; ANC=Antenatal Care; DEN=Dental clinic; EM=Emergency; ENDO=Endoscopy; ENT=Ear, Nose and Throat; EYE=Ophthalmology; GAS=Gastroenterology; GM=GeneralInternal Medicine mixed; GP=General Practitioner Practice

Antimicrobial prevalence by type of units (2)

	GYN	HCP	HIV/TB	HO	ID	OB	ORT	REN	RESP	SM
Our facility 2023–P1										
patients (N)								26	16	
treated patients (%)								19.2	25.0	
Country										
patients (N)						22				
treated patients (%)						90.9				
Continent										
patients (N)	15	93	18	25		20	16	69	44	18
treated patients (%)	40.0	12.9	100.0	4.0		90.0	0.0	31.9	52.3	0.0
Facility type										
patients (N)										
treated patients (%)										
Europe										
patients (N)	97	93		22	17	2	36	177	220	229
treated patients (%)	16.5	12.9		13.6	5.9	100.0	0.0	15.3	34.1	1.7

Patients (N) = number of patients seen in the outpatient unit(s).

Treated patients (%) = 100*(number of patients treated with at least 1 antimicrobial/number of all patients).

Country: Your country; Continent: Your continent; Facility type: Your facility type

GYN=Gynaecology; HCP=Healthcare Practice; HIV/TB=HIV–Tuberculosis; HO=Haematology–Oncology; ID=Infectious Diseases;
OB=Observation; ORT=Orthopaedic; REN=Nephrology–urology; RESP=Respiratory; SM=Surgical Mixed

Antimicrobial prevalence among adults by type of units (1)

	Total	ANC	DEN	EM	ENDO	ENT	EYE	GAS	GM	GP
Our facility 2023–P1										
patients (N)	150		7	27					56	26
treated patients (%)	32.7		14.3	29.6					53.6	7.7
Country										
patients (N)	268		1	36					174	46
treated patients (%)	54.9		100.0	19.4					54.0	76.1
Continent										
patients (N)	1313	143	28	29		37	68		671	71
treated patients (%)	31.9	25.2	42.9	31.0		40.5	1.5		34.0	50.7
Facility type										
patients (N)	136								136	
treated patients (%)	97.1								97.1	
Europe										
patients (N)	4192		1	341	3	177	103	106	2662	1
treated patients (%)	12.1		100.0	16.1	0.0	20.3	1.0	22.6	9.7	100.0

Patients (N) = number of adult patients seen in the outpatient unit(s).

Treated patients (%) = 100*(number of adult patients treated with at least 1 antimicrobial/number of all adult patients).

Country: Your country; Continent: Your continent; Facility type: Your facility type

Total=overall prevalence for all units combined; ANC=Antenatal Care; DEN=Dental clinic; EM=Emergency; ENDO=Endoscopy; ENT=Ear, Nose and Throat; EYE=Ophthalmology; GAS=Gastroenterology; GM=GeneralInternal Medicine mixed; GP=General Practitioner Practice

Antimicrobial prevalence among adults by type of units (2)

	GYN	HCP	HIV/TB	HO	ID	OB	ORT	REN	RESP	SM
Our facility 2023–P1										
patients (N)								24	10	
treated patients (%)								16.7	40.0	
Country										
patients (N)						11				
treated patients (%)						90.9				
Continent										
patients (N)	15	73	17	24		9	16	67	29	16
treated patients (%)	40.0	8.2	100.0	4.2		88.9	0.0	32.8	75.9	0.0
Facility type										
patients (N)										
treated patients (%)										
Europe										
patients (N)	97	73		22	17	2	36	175	172	204
treated patients (%)	16.5	8.2		13.6	5.9	100.0	0.0	15.4	41.3	2.0

Patients (N) = number of adult patients seen in the outpatient unit(s).

Treated patients (%) = 100*(number of adult patients treated with at least 1 antimicrobial/number of all adult patients).

Country: Your country; Continent: Your continent; Facility type: Your facility type

GYN=Gynaecology; HCP=Healthcare Practice; HIV/TB=HIV–Tuberculosis; HO=Haematology–Oncology; ID=Infectious Diseases; OB=Observation; ORT=Orthopaedic; REN=Nephrology–urology; RESP=Respiratory; SM=Surgical Mixed

Antimicrobial prevalence among children by type of units (1)

	Total	DEN	EM	ENT	EYE	GAS	GM	GP
Our facility 2023–P1								
patients (N)	51	5	10				22	7
treated patients (%)	41.2	20.0	10.0				68.2	42.9
Country								
patients (N)	198		7				134	46
treated patients (%)	74.7		14.3				69.4	95.7
Continent								
patients (N)	484	9	10	73	8	7	273	53
treated patients (%)	51.9	44.4	10.0	11.0	12.5	0.0	63.0	88.7
Facility type								
patients (N)	67						67	
treated patients (%)	97.0						97.0	
Europe								
patients (N)	1314		120	78	8		1013	
treated patients (%)	9.7		2.5	9.0	12.5		10.5	

Patients (N) = number of pediatric patients seen in the outpatient unit(s).

Treated patients (%) = $100 \times (\text{number of pediatric patients treated with at least 1 antimicrobial} / \text{number of all pediatric patients})$.

Country: Your country; Continent: Your continent; Facility type: Your facility type

Total=overall prevalence for all units combined; DEN=Dental clinic; EM=Emergency; ENT=Ear, Nose and Throat; EYE=Ophthalmology; GAS=Gastroenterology; GM=GeneralInternal Medicine mixed; GP=General Practitioner Practice

Antimicrobial prevalence among children by type of units (2)

	HCP	HIV/TB	HO	OB	REN	RESP	SM
Our facility 2023–P1							
patients (N)					2	5	
treated patients (%)					50.0	0.0	
Country							
patients (N)				11			
treated patients (%)				90.9			
Continent							
patients (N)	20	1	1	11	2	14	2
treated patients (%)	30.0	100.0	0.0	90.9	0.0	7.1	0.0
Facility type							
patients (N)							
treated patients (%)							
Europe							
patients (N)	20				2	48	25
treated patients (%)	30.0				0.0	8.3	0.0

Patients (N) = number of pediatric patients seen in the outpatient unit(s).

Treated patients (%) = $100 \times (\text{number of pediatric patients treated with at least 1 antimicrobial} / \text{number of all pediatric patients})$.

Country: Your country; Continent: Your continent; Facility type: Your facility type

HCP=Healthcare Practice; HIV/TB=HIV–Tuberculosis; HO=Haematology–Oncology; OB=Observation; REN=Nephrology–urology;
RESP=Respiratory; SM=Surgical Mixed

Antimicrobial prevalence among neonates by type of units

	Total	EM	ENT	GM	RESP
Our facility 2023–P1					
patients (N)	6	4		1	1
treated patients (%)	16.7	25.0		0.0	0.0
Country					
patients (N)	1	1			
treated patients (%)	100.0	100.0			
Continent					
patients (N)	10	4	2	3	1
treated patients (%)	10.0	25.0	0.0	0.0	0.0
Facility type					
patients (N)	1			1	
treated patients (%)	100.0			100.0	
Europe					
patients (N)	4	1	2	1	
treated patients (%)	25.0	100.0	0.0	0.0	

Patients (N) = number of neonatal patients seen in the outpatient unit(s).

Treated patients (%) = $100 \times (\text{number of neonatal patients treated with at least 1 antimicrobial} / \text{number of all neonatal patients})$.

Country: Your country; Continent: Your continent; Facility type: Your facility type

Total=Overall prevalence for all units combined; EM=Emergency; ENT=Ear, Nose and Throat; GM=General Internal Medicine mixed; RESP=Respiratory

Prevalence of patients prescribed at least one antimicrobial on day of survey

	Our facility 2023–P1		Country		Continent		Facility type		Europe	
	N	%	N	%	N	%	N	%	N	%
N patients (=denominator)	207		467		1807		204		5510	
N patients on antimicrobials	71	34.3	296	63.4	671	37.1	198	97.1	634	11.5
N patients with antibacterials for systemic use	50	24.2	249	53.3	550	30.4	145	71.1	465	8.4
N patients with antimycotics or antifungals for systemic use	0	0.0	5	1.1	9	0.5	0	0.0	7	0.1
N patients with drugs for treatment of tuberculosis	10	4.8	1	0.2	2	0.1	20	9.8	3	0.1
N patients with antivirals for systemic use	24	11.6	4	0.9	22	1.2	107	52.5	154	2.8
N patients with antibiotics used as intestinal anti-infectives	0	0.0	0	0.0	0	0.0	2	1.0	19	0.3
N patients with nitroimidazole derivatives	3	1.4	66	14.1	87	4.8	11	5.4	5	0.1
N patients with antimalarials	10	4.8	43	9.2	98	5.4	22	10.8	1	0.0

N = number of patients. ATC codes used : antibacterials for systemic use = J01; antimycotics = D01BA; antifungals for systemic use = J02; drug for the treatment of tuberculosis = J04A; antivirals for systemic use = J05; antibiotics used as intestinal anti-infectives = A07A; nitroimidazole derivatives = P01AB; antimalarials = P01B.

Country: Your country; Continent: Your continent; Facility type: Your facility type

Prevalence of adult patients prescribed at least one antimicrobial on day of survey

	Our facility 2023–P1		Country		Continent		Facility type		Europe	
	N	%	N	%	N	%	N	%	N	%
N patients (=denominator)	150		268		1313		136		4192	
N patients on antimicrobials	49	32.7	147	54.9	419	31.9	132	97.1	506	12.1
N patients with antibacterials for systemic use	34	22.7	123	45.9	330	25.1	86	63.2	348	8.3
N patients with antimycotics or antifungals for systemic use	0	0.0	2	0.7	5	0.4	0	0.0	7	0.2
N patients with drugs for treatment of tuberculosis	9	6.0	0	0.0	1	0.1	19	14.0	1	0.0
N patients with antivirals for systemic use	23	15.3	4	1.5	21	1.6	102	75.0	145	3.5
N patients with antibiotics used as intestinal anti-infectives	0	0.0	0	0.0	0	0.0	0	0.0	19	0.5
N patients with nitroimidazole derivatives	1	0.7	47	17.5	63	4.8	5	3.7	4	0.1
N patients with antimalarials	4	2.7	16	6.0	65	5.0	8	5.9	1	0.0

N = number of adult patients. ATC codes used : antibacterials for systemic use = J01; antimycotics = D01BA; antifungals for systemic use = J02; drug for the treatment of tuberculosis = J04A; antivirals for systemic use = J05; antibiotics used as intestinal anti-infectives = A07A; nitroimidazole derivatives = P01AB; antimalarials = P01B.

Country: Your country; Continent: Your continent; Facility type: Your facility type

Prevalence of pediatric patients prescribed at least one antimicrobial on day of survey

	Our facility 2023–P1		Country		Continent		Facility type		Europe	
	N	%	N	%	N	%	N	%	N	%
N patients (=denominator)	51		198		484		67		1314	
N patients on antimicrobials	21	41.2	148	74.7	251	51.9	65	97.0	127	9.7
N patients with antibacterials for systemic use	15	29.4	126	63.6	219	45.2	58	86.6	117	8.9
N patients with antimycotics or antifungals for systemic use	0	0.0	3	1.5	4	0.8	0	0.0	0	0.0
N patients with drugs for treatment of tuberculosis	1	2.0	0	0.0	1	0.2	1	1.5	1	0.1
N patients with antivirals for systemic use	1	2.0	0	0.0	1	0.2	5	7.5	9	0.7
N patients with antibiotics used as intestinal anti-infectives	0	0.0	0	0.0	0	0.0	2	3.0	0	0.0
N patients with nitroimidazole derivatives	2	3.9	19	9.6	24	5.0	6	9.0	1	0.1
N patients with antimalarials	6	11.8	27	13.6	33	6.8	14	20.9	0	0.0

N = number of pediatric patients. ATC codes used : antibacterials for systemic use = J01; antimycotics = D01BA; antifungals for systemic use = J02; drug for the treatment of tuberculosis = J04A; antivirals for systemic use = J05; antibiotics used as intestinal anti-infectives = A07A; nitroimidazole derivatives = P01AB; antimalarials = P01B.

Country: Your country; Continent: Your continent; Facility type: Your facility type


Prevalence of neonatal patients prescribed at least one antimicrobial on day of survey

	Our facility 2023–P1		Country		Continent		Facility type		Europe	
	N	%	N	%	N	%	N	%	N	%
N patients (=denominator)	6				10					
N patients on antimicrobials	1	16.7			1	10.0				
N patients with antibacterials for systemic use	1	16.7			1	10.0				
N patients with antimycotics or antifungals for systemic use	0	0.0			0	0.0				
N patients with drugs for treatment of tuberculosis	0	0.0			0	0.0				
N patients with antivirals for systemic use	0	0.0			0	0.0				
N patients with antibiotics used as intestinal anti-infectives	0	0.0			0	0.0				
N patients with nitroimidazole derivatives	0	0.0			0	0.0				
N patients with antimalarials	0	0.0			0	0.0				

N = number of neonatal patients. ATC codes used : antibacterials for systemic use = J01; antimycotics = D01BA; antifungals for systemic use = J02; drug for the treatment of tuberculosis = J04A; antivirals for systemic use = J05; antibiotics used as intestinal anti-infectives = A07A; nitroimidazole derivatives = P01AB; antimalarials = P01B.

Country: Your country; Continent: Your continent; Facility type: Your facility type


Overall proportional antibiotic use (% of prescriptions)



Percentage of antibacterials for systemic use (ATC J01, P01AB, A07A, J04A) at ATC3 level (pharmacological subgroup).
 Proportional antibiotic use below 0.5% is not reported. fac = facilities, surv = surveys, prescr = prescriptions.

Country: Your country; Continent: Your continent; Facility type: Your facility type


Overall proportional antibiotic use (% of prescriptions) among adults



Percentage of antibacterials for systemic use (ATC J01, P01AB, A07A, J04A) at ATC3 level (pharmacological subgroup) among adults. Proportional antibiotic use below 0.5% is not reported. fac = facilities, surv = surveys, prescr = prescriptions.

Country: Your country; Continent: Your continent; Facility type: Your facility type


Overall proportional antibiotic use (% of prescriptions) among children



Percentage of antibacterials for systemic use (ATC J01, P01AB, A07A, J04A) at ATC3 level (pharmacological subgroup) among children. Proportional antibiotic use below 0.5% is not reported. fac = facilities, surv = surveys, prescr = prescriptions.

Country: Your country; Continent: Your continent; Facility type: Your facility type

Overall proportional antibiotic use (% of prescriptions) among neonates



Percentage of antibacterials for systemic use (ATC J01, P01AB, A07A, J04A) at ATC3 level (pharmacological subgroup) among neonates. Proportional antibiotic use below 0.5% is not reported. fac = facilities, surv = surveys, prescr = prescriptions.

Country: Your country; Continent: Your continent; Facility type: Your facility type

Proportional antibiotic use (% of prescriptions)

ATC4	Antibiotics Subgroup	Our Facility	Country	Continent	Type	Europe
J01AA	Tetracyclines		4.5	2.9		0.6
J04AM	Comb. drugs for tuberculosis	13.6		0.1	9.2	0.2
P01AB	Nitroimidazole derivatives	4.5	19.8	12.9	4.6	1.2
J01CA	Penicillins with extended spectrum	13.6	43.5	24.1	17.6	7.7
J01CE	Beta-lactamase sensitive penicillins	6.1	1.8	0.9	2.3	0.4
J01CF	Beta-lactamase resistant penicillins	1.5	0.3	0.9	2.9	0.2
J01CR	Penicillins incl. beta-lactam. inh.	12.1	4.2	13.7	7.5	28.3
J01DB	First-generation cephalosporins	1.5		0.3		1.0
J01DD	Third-generation cephalosporins	6.1	6.3	11.3	1.3	21.9
J01DE	Fourth-generation cephalosporins	1.5				
J01EE	Comb. Sulfonamides/trimethoprim	18.2	9.9	4.9	39.9	0.6
J01FA	Macrolides	7.6	2.4	7.8	7.2	14.2
J01FF	Lincosamides	1.5		0.7	1.0	0.8
J01GB	Other aminoglycosides		0.6	0.1	0.3	0.2
J01MA	Fluoroquinolones	10.6	5.7	13.2	2.6	15.2

Our facility: 66 prescriptions, 59 treated patients; Country: 333 prescriptions, 15 facilities, 15 surveys
 Continent: 680 prescriptions, 19 facilities, 19 surveys; Type: 403 prescriptions, 12 facilities, 12 surveys

Europe: 520 prescriptions, 21 facilities, 21 surveys

Country: Your country ; Continent: Your continent ; Facility type: Your facility type

10 most prescribed ATC4 antibiotics (ATC J01, P01AB, A07A, J04A) at country level plus 5 extra ATC4 at facility level
 which do not fall within top 10 at country level

Proportional antibiotic use (% of prescriptions) among adults

ATC4	Antibiotics Subgroup	Our Facility	Country	Continent	Type	Europe
J01AA	Tetracyclines		8.2	4.7		0.8
J04AM	Comb. drugs for tuberculosis	17.0		0.2	12.5	0.3
P01AB	Nitroimidazole derivatives	2.1	25.5	15.0	3.7	1.3
J01CA	Penicillins with extended spectrum	10.6	32.6	17.3	10.2	5.8
J01CE	Beta-lactamase sensitive penicillins	6.4	1.1	0.5	2.3	0.5
J01CF	Beta-lactamase resistant penicillins		0.5	0.5	1.4	0.3
J01CR	Penicillins incl. beta-lactam. inh.	6.4	5.4	15.2	9.3	29.2
J01DB	First-generation cephalosporins	2.1		0.2		1.0
J01DD	Third-generation cephalosporins	6.4	7.1	7.0	1.4	17.6
J01EE	Comb. Sulfonamides/trimethoprim	25.5	7.6	3.3	49.1	0.8
J01FA	Macrolides	6.4	1.1	8.4	1.4	13.6
J01FF	Lincosamides	2.1		0.9	1.4	1.0
J01MA	Fluoroquinolones	12.8	9.2	19.7	2.8	19.1

Our facility: 47 prescriptions, 41 treated patients; Country: 184 prescriptions, 13 facilities, 13 surveys
 Continent: 427 prescriptions, 18 facilities, 18 surveys; Type: 216 prescriptions, 11 facilities, 11 surveys

Europe: 397 prescriptions, 18 facilities, 18 surveys

Country: Your country ; Continent: Your continent ; Facility type: Your facility type

10 most prescribed ATC4 antibiotics (ATC J01, P01AB, A07A, J04A) at country level plus 5 extra ATC4 at facility level
 which do not fall within top 10 at country level

Proportional antibiotic use (% of prescriptions) among children

ATC4	Antibiotics Subgroup	Our Facility	Country	Continent	Type	Europe
J01CA	Penicillins with extended spectrum	16.7	57.4	35.3	36.0	
J01CE	Beta-lactamase sensitive penicillins	5.6	2.7	1.6	2.2	
J01CF	Beta-lactamase resistant penicillins	5.6		1.6	5.6	
J01CR	Penicillins incl. beta-lactam. inh.	27.8	2.7	11.1	3.4	
J01DD	Third-generation cephalosporins	5.6	5.4	18.7	1.1	
J01DE	Fourth-generation cephalosporins	5.6				
J01EE	Comb. Sulfonamides/trimethoprim		12.8	7.5	18.0	
J01FA	Macrolides	11.1	4.1	6.7	21.3	
J01GB	Other aminoglycosides		0.7	0.4		
J01MA	Fluoroquinolones	5.6	1.4	2.4	2.2	
J04AM	Comb. drugs for tuberculosis	5.6			1.1	
P01AB	Nitroimidazole derivatives	11.1	12.8	9.5	6.7	

Our facility: 18 prescriptions, 17 treated patients; Country: 148 prescriptions, 10 facilities, 10 surveys
 Continent: 252 prescriptions, 17 facilities, 17 surveys; Type: 89 prescriptions, 9 facilities, 9 surveys

Country: Your country ; Continent: Your continent ; Facility type: Your facility type
 10 most prescribed ATC4 antibiotics (ATC J01, P01AB, A07A, J04A) at country level plus 5 extra ATC4 at facility level
 which do not fall within top 10 at country level

Proportional antibiotic use (% of prescriptions) among neonates

ATC4	Antibiotics Subgroup	Our Facility	Country	Continent	Type	Europe
J01CA	Penicillins with extended spectrum	100.0				

Our facility: 1 prescriptions, 1 treated patients; Country: 1 prescriptions, 1 facilities, 1 surveys

Country: Your country ; Continent: Your continent ; Facility type: Your facility type
10 most prescribed ATC4 antibiotics (ATC J01, P01AB, A07A, J04A) at country level plus 5 extra ATC4 at facility level
which do not fall within top 10 at country level

Ten most common diagnoses for which at least one antimicrobial was prescribed

Diagnosis	Our facility 2023–P1		Country		Continent		Facility type		Europe	
	N	%	N	%	N	%	N	%	N	%
MP–GEN	24	24.7			20	2.9	78	25.4	6	0.9
HIV	20	20.6	1	0.3	18	2.6	107	34.9	1	0.2
Malaria	10	10.3	40	12.7	63	9.0	22	7.2		
URTI	5	5.2	123	38.9	155	22.2	3	1.0	168	26.2
Other	4	4.1	5	1.6	75	10.8	9	2.9	85	13.3
Pneu	4	4.1	6	1.9	18	2.6	2	0.7	26	4.1
Typh–fever	4	4.1	8	2.5	10	1.4	11	3.6		
GI	3	3.1	29	9.2	38	5.5	4	1.3	42	6.6
Proph CVS	3	3.1	2	0.6	2	0.3			2	0.3
Bron	2	2.1	2	0.6	11	1.6	15	4.9	74	11.6
Cys	1	1.0	24	7.6	68	9.8			20	3.1
SST	2	2.1	19	6.0	36	5.2	8	2.6	19	3.0

Top ten diagnoses among patients in our facility, supplemented with the top 5 in the country and top 5 in the continent if they fall outside the top 10 of the facility. Max. 15 diagnoses are shown. The number of diagnoses treated with at least 1 antimicrobial are counted. This implies that a patient with multiple diagnoses can be counted several times.

Country: Your country; Continent: Your continent; Facility type: Your facility type
 URTI=Upper respiratory tract infections; Bron=Acute bronchitis or exacerbations of chronic bronchitis; Pneu=Pneumonia or lower respiratory tract infections; Proph CVS=Cardiac or Vascular prophylaxis; GI=Gastro–intestinal infections;
 SST=Skin and soft tissue infections; Cys=Lower urinary tract infection; Typh–fever=Typhoid fever or enteric fever;
 Other=Other, no defined diagnosis group; MP–GEN=Medical Prophylaxis in general targeting no specific site

Ten most common diagnoses for which at least one antimicrobial was prescribed among adults

Diagnosis	Our facility 2023–P1		Country		Continent		Facility type		Europe	
	N	%	N	%	N	%	N	%	N	%
MP–GEN	22	30.6			17	3.9	74	33.3	5	1.0
HIV	19	26.4	1	0.6	17	3.9	102	45.9	1	0.2
Malaria	4	5.6	14	9.1	31	7.2	8	3.6		
Other	3	4.2	3	1.9	50	11.6	6	2.7	60	11.7
Pneu	3	4.2	3	1.9	13	3.0	1	0.5	24	4.7
Proph CVS	3	4.2	2	1.3	2	0.5			2	0.4
Bron	2	2.8	2	1.3	11	2.5	3	1.4	64	12.5
GI	2	2.8	20	13.0	27	6.2	3	1.4	41	8.0
Typh–fever	2	2.8	7	4.5	9	2.1	7	3.2		
CNS	1	1.4			1	0.2			2	0.4
URTI	1	1.4	43	27.9	50	11.6			128	25.0
Cys	1	1.4	22	14.3	62	14.4			19	3.7
SST	1	1.4	11	7.1	18	4.2	1	0.5	15	2.9

Top ten diagnoses among adult patients in our facility, supplemented with the top 5 in the country and top 5 in the continent if they fall outside the top 10 of the facility. Max. 15 diagnoses are shown. The number of diagnoses treated with at least 1 antimicrobial are counted. This implies that a patient with multiple diagnoses can be counted several times.

Country: Your country; Continent: Your continent; Facility type: Your facility type
 CNS=Infections of the Central Nervous System; URTI=Upper respiratory tract infections; Bron=Acute bronchitis or exacerbations of chronic bronchitis; Pneu=Pneumonia or lower respiratory tract infections; Proph CVS=Cardiac or Vascular prophylaxis; GI=Gastro–intestinal infections; SST=Skin and soft tissue infections; Cys=Lower urinary tract infection; Typh–fever=Typhoid fever or enteric fever; Other=Other, no defined diagnosis group; MP–GEN=Medical Prophylaxis in general targeting no specific site

Ten most common diagnoses for which at least one antimicrobial was prescribed among children

Diagnosis	Our facility 2023–P1		Country		Continent		Facility type		Europe	
	N	%	N	%	N	%	N	%	N	%
Malaria	6	25.0	26	16.1	32	12.1	14	16.7		
URTI	3	12.5	80	49.7	104	39.4	3	3.6	40	31.2
MP–GEN	2	8.3			3	1.1	4	4.8	1	0.8
Typh–fever	2	8.3	1	0.6	1	0.4	4	4.8		
CVS	1	4.2								
GI	1	4.2	9	5.6	11	4.2	1	1.2	1	0.8
HIV	1	4.2			1	0.4	5	6.0		
OBGY	1	4.2	1	0.6	1	0.4	1	1.2		
Other	1	4.2	2	1.2	25	9.5	3	3.6	25	19.5
Pneu	1	4.2	3	1.9	5	1.9	1	1.2	2	1.6
SST	1	4.2	8	5.0	18	6.8	6	7.1	4	3.1
GO			9	5.6	12	4.5	4	4.8	2	1.6

Top ten diagnoses among pediatric patients in our facility, supplemented with the top 5 in the country and top 5 in the continent if they fall outside the top 10 of the facility. Max. 15 diagnoses are shown. The number of diagnoses treated with at least 1 antimicrobial are counted. This implies that a patient with multiple diagnoses can be counted several times.

Country: Your country; Continent: Your continent; Facility type: Your facility type
 URTI=Upper respiratory tract infections; Pneu=Pneumonia or lower respiratory tract infections; CVS=Cardiovascular system infections; GO=Acute Infectious Diarrhea; GI=Gastro–intestinal infections; SST=Skin and soft tissue infections; OBGY=Obstetric/Gynaecological infections; Typh–fever=Typhoid fever or enteric fever; Other=Other, no defined diagnosis group; MP–GEN=Medical Prophylaxis in general targeting no specific site


Ten most common diagnoses for which at least one antimicrobial was prescribed among neonates

Diagnosis	Our facility 2023–P1		Country		Continent		Facility type		Europe	
	N	%	N	%	N	%	N	%	N	%
URTI	1	100.0			1	100.0				
Proph CNS			1	100.0					1	100.0

Top ten diagnoses among neonatal patients in our facility, supplemented with the top 5 in the country and top 5 in the continent if they fall outside the top 10 of the facility. Max. 15 diagnoses are shown. The number of diagnoses treated with at least 1 antimicrobial are counted. This implies that a patient with multiple diagnoses can be counted several times.

Country: Your country; Continent: Your continent; Facility type: Your facility type
Proph CNS=Prophylaxis for Central Nervous System cases; URTI=Upper respiratory tract infections


Top 5 most frequently used antimicrobials (% prescriptions) for Medical Prophylaxis in general targeting no specific site



Top 5 most prescribed antimicrobials (ATC5, substance level) for Medical Prophylaxis in general targeting no specific site at facility level, supplemented with the most prescribed antimicrobials at country, continental and facility type level if they do not fall within top 5 of the facility. Selection on diagnostic code is MP-GEN=Medical Prophylaxis in general targeting no specific site;

Country: Your country; Continent: Your continent; Facility type: Your facility type


Top 5 most frequently used antimicrobials (% prescriptions) for HIV



Top 5 most prescribed antimicrobials (ATC5, substance level) for HIV at facility level, supplemented with the most prescribed antimicrobials at country, continental and facility type level if they do not fall within top 5 of the facility. Selection on diagnostic code is HIV;

Country: Your country; Continent: Your continent; Facility type: Your facility type


Top 5 most frequently used antimicrobials (% prescriptions) for Malaria



Top 5 most prescribed antimicrobials (ATC5, substance level) for Malaria at facility level, supplemented with the most prescribed antimicrobials at country, continental and facility type level if they do not fall within top 5 of the facility. Selection on diagnostic code is Malaria;

Country: Your country; Continent: Your continent; Facility type: Your facility type


Top 5 most frequently used antimicrobials (% prescriptions) for Upper respiratory tract infections



Top 5 most prescribed antimicrobials (ATC5, substance level) for Upper respiratory tract infections at facility level, supplemented with the most prescribed antimicrobials at country, continental and facility type level if they do not fall within top 5 of the facility. Selection on diagnostic code is URTI=Upper respiratory tract infections;

Country: Your country; Continent: Your continent; Facility type: Your facility type


Top 5 most frequently used antimicrobials (% prescriptions) for Other, no defined diagnosis group



Top 5 most prescribed antimicrobials (ATC5, substance level) for Other, no defined diagnosis group at facility level, supplemented with the most prescribed antimicrobials at country, continental and facility type level if they do not fall within top 5 of the facility. Selection on diagnostic code is Other=Other, no defined diagnosis group;

Country: Your country; Continent: Your continent; Facility type: Your facility type

Top 5 most frequently used antimicrobials (% prescriptions) for Medical Prophylaxis in general targeting no specific site among adults




Top 5 most prescribed antimicrobials (ATC5, substance level) for Medical Prophylaxis in general targeting no specific site at facility level among adults, supplemented with the most prescribed antimicrobials at country, continental and facility type level if they do not fall within top 5 of the facility. Selection on diagnostic code is MP-GEN=Medical

Prophylaxis in general targeting no specific site;

Country: Your country; Continent: Your continent; Facility type: Your facility type


Top 5 most frequently used antimicrobials (% prescriptions) for HIV among adults



Top 5 most prescribed antimicrobials (ATC5, substance level) for HIV at facility level among adults , supplemented with the most prescribed antimicrobials at country, continental and facility type level if they do not fall within top 5 of the facility. Selection on diagnostic code is HIV;

Country: Your country; Continent: Your continent; Facility type: Your facility type


Top 5 most frequently used antimicrobials (% prescriptions) for Malaria among adults



Top 5 most prescribed antimicrobials (ATC5, substance level) for Malaria at facility level among adults, supplemented with the most prescribed antimicrobials at country, continental and facility type level if they do not fall within top 5 of the facility. Selection on diagnostic code is Malaria;

Country: Your country; Continent: Your continent; Facility type: Your facility type


Top 5 most frequently used antimicrobials (% prescriptions) for Other, no defined diagnosis group among adults



Top 5 most prescribed antimicrobials (ATC5, substance level) for Other, no defined diagnosis group at facility level among adults, supplemented with the most prescribed antimicrobials at country, continental and facility type level if they do not fall within top 5 of the facility. Selection on diagnostic code is Other=Other, no defined diagnosis group;

Country: Your country; Continent: Your continent; Facility type: Your facility type


Top 5 most frequently used antimicrobials (% prescriptions) for Pneumonia or lower respiratory tract infections among adults



Top 5 most prescribed antimicrobials (ATC5, substance level) for Pneumonia or lower respiratory tract infections at facility level among adults, supplemented with the most prescribed antimicrobials at country, continental and facility type level if they do not fall within top 5 of the facility. Selection on diagnostic code is Pneu=Pneumonia or lower respiratory tract infections;

Country: Your country; Continent: Your continent; Facility type: Your facility type


Top 5 most frequently used antimicrobials (% prescriptions) for Malaria among children



Top 5 most prescribed antimicrobials (ATC5, substance level) for Malaria at facility level among children , supplemented with the most prescribed antimicrobials at country, continental and facility type level if they do not fall within top 5 of the facility. Selection on diagnostic code is Malaria;

Country: Your country; Continent: Your continent; Facility type: Your facility type

Top 5 most frequently used antimicrobials (% prescriptions) for Upper respiratory tract infections among children



Top 5 most prescribed antimicrobials (ATC5, substance level) for Upper respiratory tract infections at facility level among children, supplemented with the most prescribed antimicrobials at country, continental and facility type level if they do not fall within top 5 of the facility. Selection on diagnostic code is URTI=Upper respiratory tract infections;

Country: Your country; Continent: Your continent; Facility type: Your facility type

Explanatory notes for the slides on AWaRe antibiotic use

The following slides present antibiotic prescribing patterns according to the WHO Access, Watch, Reserve (AWaRe) classification. Antibiotic prescriptions for systemic use (ATC J01, P01AB, A07A, J04A) are classified into 4 categories:

Access

1st or 2nd choice for empiric treatment of the most common infections
Lower risk of resistance selection
Amoxicillin, cefazolin, cloxacillin, clindamycin...

Watch

1st or 2nd choice for limited indications only
Higher risk of resistance selection
Quinolones, carbapenems, cephalosporins 2nd / 3rd gen...

Reserve

To be used only as a last resort, when no other alternatives are available
Colistin, linezolid, tigecyclin...

Not recommended (new category 2019)

Mainly fixed-dose combinations of broad-spectrum antibiotics


Unclassified

Antibiotics to which an AWaRe code has not (yet) been assigned


More info on the WHO AWaRe classification:

<https://adoptaware.org/>


Overall antibiotic use (% prescriptions) according to the WHO AWaRe classification




Overall antibiotic use (% prescriptions) according to the WHO AWaRe classification among adults



Overall antibiotic use (% prescriptions) according to the WHO AWaRe classification among children



Overall antibiotic use (% prescriptions) according to the WHO AWaRe classification among neonates



Explanatory notes for the slides on guideline–related quality indicators

The following slides present the availability of and compliance to local guidelines among all prescriptions. The availability and compliance are calculated, together with the percentage (%) of unknown available/compliant prescriptions, as follows:

Availability of guidelines

Numerator is the number of prescriptions. Denominator is the total number of prescriptions.

The availability of guidelines can be one of the following values: Yes, No, Unknown indication or Unknown.

Unknown indication is selected when the diagnosis is not known.

Guideline compliance

Numerator is the number of guideline compliant (Yes) prescriptions at patient– and diagnosis–level, meaning that compliance is calculated for each diagnosis of a patient. For combination therapy with >1 antimicrobial: if 1 antimicrobial by diagnosis is not compliant, the whole combination therapy is counted as non–compliant. Denominator is the number of compliant (Yes) and non–compliant (No) prescriptions at patient– and diagnosis–level.

Not available compliance

Numerator is the number of unknown compliant prescriptions (Unknown or Not Available) at patient– and diagnosis–level, meaning that compliance is calculated for each diagnosis of a patient. For combination therapy with >1 antimicrobial: if 1 antimicrobial by diagnosis has unknown compliance, this whole combination therapy is counted as unknown–compliant. Denominator is the number of compliant (Yes), non–compliant (No) and unknown compliant (Unknown or Not Available) prescriptions at patient– and diagnosis–level.

Guideline-related quality indicators for antimicrobial use

	Our facility 2023-P1		Country		Continent		Facility type		Europe	
	N	%	N	%	N	%	N	%	N	%
N prescriptions	103		387		849		331		683	
Availability of guidelines										
Yes	84	81.6	338	87.3	462	54.4	299	90.3	462	67.6
No	7	6.8	4	1	16	1.9	8	2.4	31	4.5
Unknown indication (NI)	6	5.8	21	5.4	342	40.3	24	7.3	167	24.5
Unknown	6	5.8	24	6.2	29	3.4	0	0	23	3.4
Drug										
Yes	68	87.2	201	73.1	272	77.5	219	78.8	350	82
Dose										
Yes	59	80.8	172	62.5	239	69.1	204	80.3	347	81.5
Not available	5	6.8	2	0.8	6	1.7	26	11.1	5	1.3
Duration										
Yes	57	81.4	199	72.4	268	77.5	198	86.8	324	77.3
Not available	8	10.8	2	0.8	6	1.7	53	22.6	12	3.2
Route of administration										
Yes	5	62.5	31	43.1	31	41.3	0	0	8	80
Not available	70	94.6	206	84.8	278	76.6	278	118.3	421	111.4

Detailed information on compliance to the type of drug, dose and duration are only available if 'guideline exist' equals 'Yes'.

Guideline-related quality indicators for antimicrobial use among adults

	Our facility 2023-P1		Country		Continent		Facility type		Europe	
	N	%	N	%	N	%	N	%	N	%
N prescriptions	76		207		555		234		551	
Availability of guidelines										
Yes	64	84.2	178	86	274	49.4	225	96.2	398	72.2
No	4	5.3	3	1.4	11	2	2	0.9	27	4.9
Unknown indication (NI)	4	5.3	13	6.3	254	45.8	7	3	104	18.9
Unknown	4	5.3	13	6.3	16	2.9	0	0	22	4
Drug										
Yes	53	88.3	100	75.8	152	80.9	182	85.4	296	81.3
Dose										
Yes	48	81.4	92	69.2	141	76.2	183	89.3	285	78.5
Not available	1	1.8	1	0.8	3	1.3	10	5.3	4	1.2
Duration										
Yes	46	79.3	99	75	150	81.1	179	89.5	267	75
Not available	2	3.5	2	1.5	3	1.3	16	8.5	11	3.4
Route of administration										
Yes	3	50	19	55.9	18	50	0	0	7	87.5
Not available	54	94.7	101	76.5	153	67.7	213	112.7	359	110.8

Detailed information on compliance to the type of drug, dose and duration are only available if 'guideline exist' equals 'Yes'.

Guideline–related quality indicators for antimicrobial use among children

	Our facility 2023–P1		Country		Continent		Facility type		Europe	
	N	%	N	%	N	%	N	%	N	%
N prescriptions	26		179		293		96		131	
Availability of guidelines										
Yes	20	76.9	159	88.8	188	64.2	73	76	63	48.1
No	3	11.5	1	0.6	5	1.7	6	6.2	4	3.1
Unknown indication (NI)	2	7.7	8	4.5	88	30	17	17.7	63	48.1
Unknown	1	3.8	11	6.1	12	4.1	0	0	1	0.8
Drug										
Yes	15	83.3	101	71.1	120	73.6	36	56.2	54	87.1
Dose										
Yes	11	78.6	80	56.7	98	60.9	21	43.8	62	100
Not available	4	23.5	1	0.9	3	2.2	16	35.6	1	1.9
Duration										
Yes	11	91.7	100	70.4	118	73.3	19	67.9	57	91.9
Not available	6	35.3	0	0	3	2.2	36	80	1	1.9
Route of administration										
Yes	2	100	12	31.6	13	33.3	0	0	1	50
Not available	16	94.1	104	93.7	125	91.2	64	142.2	61	113

Detailed information on compliance to the type of drug, dose and duration are only available if 'guideline exist' equals 'Yes'.

Guideline–related quality indicators for antimicrobial use among neonates

	Our facility 2023–P1		Country		Continent		Facility type		Europe	
	N	%	N	%	N	%	N	%	N	%
N prescriptions	1				1					
Availability of guidelines										
Yes	0	0			0	0				
No	0	0			0	0				
Unknown indication (NI)	0	0			0	0				
Unknown	1	100			1	100				
Drug										
Yes	0	0			0	0				
Dose										
Yes	0	0			0	0				
Not available	0	0			0	0				
Duration										
Yes	0	0			0	0				
Not available	0	0			0	0				
Route of administration										
Yes	0	0			0	0				
Not available	0	0			0	0				

Detailed information on compliance to the type of drug, dose and duration are only available if 'guideline exist' equals 'Yes'.